Prof Marco Gerlinger

Marco Gerlinger

Head of the Translational Cancer Genomics and Immunotherapy Lab, Consultant Oncologist

Barts Cancer Institute
Queen Mary University of London

Research

Patient Derived Organoids, Immunotherapy, Antibody Drug Conjugates, Biomarkers, Mechanisms of therapy sensitivity and resistance, gastrointestinal cancers

Cancer Models

Interests

My lab is using patient derived organoids (as monoculture or co-culture for example with T cells) from gastrointestinal cancers as in vitro models to assess mechanisms or resistance and sensitivity to novel therapeutics such as immunotherapies and ADCs. We are also investigating novel combination therapies in these.

Publications

solid heart iconPublications of specific relevance to Predictive in vitro Models

2026

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation
Flanders L, Savy T, Ficial M, Al-Ghraibawi N, Barber L, Slater S, Pihlak R, Propper D et al.
British Journal of Cancer, Springer Nature, 1-8.  
18-04-2026

2025

Phenotypic heterogeneity and plasticity in colorectal cancer metastasis
Ogden S, Metic N, Leylek O, Smith EA, Berner AM, Baker A-M, Uddin I, Buzzetti M et al.
Cell Genomics, Elsevier vol. 5 (7) 
19-05-2025
Deep learning for liver lesion segmentation and classification on staging CT scans of colorectal cancer patients: A multi-site technical validation study
Bashir U, Wang C, Smillie R, Khan AKR, Ahmed HT, Ordidge K, Power N, Gerlinger M et al.
Clinical Radiology, Elsevier, 106914-106914.  
01-04-2025
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis
Savy T, Flanders L, Karpanasamy T
Trends in Cancer, Elsevier vol. 11 (3), 204-215.  
28-01-2025
Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy
Millar L, Di Marco Barros R, Kapiris M, Nikolaou C, Gerlinger M, Wu Y
Clinical & Experimental Immunology, Oxford University Press (Oup) vol. 219 (1) 
21-01-2025

2024

Resistance Management for Cancer: Lessons from Farmers
Seyedi S, Harris VK, Kapsetaki SE, Narayanan S, Saha D, Compton Z, May A, Fakir E et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 84 (22), 3715-3727.  
02-10-2024
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer
Saeed A, Tabernero J, Parikh A, Van den Eynde M, Karthaus M, Wang G, Hecht JR
Future Oncology, Taylor & Francis vol. 20 (24), 1733-1743.  
23-07-2024
124P Acquired resistance to first-line chemo- and EGFRab-therapy in mCRC: Biopsy analysis of the iSCORE trial
Lane R, Mencel J, Turkes F, Challoner BR, McCafferty N, Ntellas P, Barber LJ, Rana I et al.
 
01-06-2024
30P Immunological markers of pathological and clinical and outcomes in mismatch repair deficient (MMRd) colorectal cancer (CRC)
Challoner BR, Slater SC, Sansano HB, Aresu M, Bryant A, Begum R, Rana T, Zhitkov O et al.
 
01-06-2024
State of the art: Targeting microsatellite instability in gastrointestinal cancers
Mencel J, Alves A, Angelis V, Gerlinger M, Starling N
Critical Reviews in Oncology/Hematology, Elsevier vol. 199 
10-05-2024

2023

Assessing the toxicity of bispecific antibodies
Buzzetti M, Gerlinger M
Nature Biomedical Engineering, Springer Nature vol. 8 (4), 339-340.  
22-12-2023
Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ
Newey A, Yu L, Barber LJ
Cancer Research Communications, American Association For Cancer Research (Aacr) vol. 3 (11), 2345-2357.  
17-11-2023
Genetic and immune landscape evolution in MMR‐deficient colorectal cancer
Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, Anandappa G, Crux R et al.
The Journal of Pathology, Wiley vol. 262 (2), 226-239.  
15-11-2023
P-111 PD1 and LAG3 inhibition as second+ line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer
Mencel J, Turkes F, Barber L, Challoner B, Buzzetti M, Tran A, Chen H, McCafferty N et al.
 
01-06-2023
Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer
Alexander JL, Posma JM, Scott A, Poynter L, Mason SE, Doria ML, Herendi L, Roberts L et al.
Microbiome, Springer Nature vol. 11 (1) 
08-05-2023
Abstract 5591: Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma
Gerlinger M, Gordon A, Barber LJ, Laliotis G, Athauda A, Challoner B, Woolston A, Mansukhani S et al.
 
04-04-2023
Abstract 5593: Clonal mutation burden and evolutionary dynamics analysis in metastatic gastro-esophageal adenocarcinoma (GEA) by error corrected whole-exome circulating tumor DNA sequencing
McCafferty N, Fong C, Barber LJ, Woolston A, Kleftogiannis D, Cromarty S, Kidd S, Begum R
 
04-04-2023
Impact of infiltrating T cell subtypes on survival and response to FLOT chemotherapy in resectable oesophagogastric adenocarcinoma (OGA).
Athauda A, Silveira T, Lund T, von Loga K, Challoner B, Rana I, Thomas J, Starling N et al.
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 41 (4_suppl), 443-443.  
24-01-2023
Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA).
Gordon A, Challoner B, Athauda A, Woolston A, Mansukhani S, Dunstan M, Petrou N, Khabra K et al.
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 41 (4_suppl), 446-446.  
24-01-2023

2022

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance
Torlot L, Jarzab A, Albert J, Pók-Udvari Á, Stahler A, Holch JW, Gerlinger M, Heinemann V et al.
Journal of Cancer Research and Clinical Oncology, Springer Nature vol. 149 (2), 669-682.  
19-11-2022
Advances in immunotherapy for MMR proficient colorectal cancer
Lote H, Starling N, Pihlak R, Gerlinger M
Cancer Treatment Reviews, Elsevier vol. 111 
01-11-2022
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
Büttner FA, Winter S, Stühler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, Meinhardt M et al.
Genome Medicine, Springer Nature vol. 14 (1) 
15-09-2022
Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors
Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Richtig G, Bracht JWP et al.
Jco Precision Oncology, American Society of Clinical Oncology (Asco) vol. 6 (6) 
01-08-2022
Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes
Somarelli JA, DeGregori J, Gerlinger M, Heng HH, Marusyk A, Welch DR, Laukien FH
Medical Oncology, Springer Nature vol. 39 (9) 
04-07-2022
Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer
Challoner BR, Woolston A, Lau D, Buzzetti M, Barber LJ, Lund T, Sansano HB, von Loga K et al.
 
15-05-2022
Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer
Challoner BR, Woolston A, Lau D, Buzzetti M, Barber LJ, Lund T, Sansano HB, von Loga K et al.
 
15-05-2022
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study
Moussa O, Bhogal RH, Malietzis G, Fribbens C, Starling N, Gerlinger M, Watkins D, Chau I et al.
Bjs Open, Oxford University Press (Oup) vol. 6 (1) 
06-01-2022

2021

Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer
Woolston A, Barber LJ, Griffiths B, Pich O, Lopez-Bigas N, Matthews N, Rao S, Watkins D et al.
Nature Ecology & Evolution, Springer Nature vol. 5 (7), 1024-1032.  
20-05-2021
Identifying key questions in the ecology and evolution of cancer
Dujon AM, Aktipis A, Alix‐Panabières C, Amend SR, Boddy AM, Brown JS, Capp J, DeGregori J et al.
Evolutionary Applications, Wiley vol. 14 (4), 877-892.  
08-02-2021
Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough
Gerlinger M
Cancer Cell, Elsevier vol. 39 (1), 16-18.  
01-01-2021

2020

Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy
Knebel FH, Barber LJ, Newey A, Kleftogiannis D, Woolston A, Fenwick K, Bettoni F, Ribeiro MFSA et al.
Cancers, Mdpi vol. 12 (12) 
11-12-2020
Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data
Khan K, Gonzalez-Exposito R, Cunningham D, Koh D-M, Woolston A, Barber L, Griffiths B, Kouvelakis K et al.
Frontiers in Oncology, Frontiers vol. 10 
04-09-2020
Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk
Fotiadis N, De Paepe KN, Bonne L, Khan N, Riddell A, Turner N, Starling N, Gerlinger M et al.
European Radiology, Springer Nature vol. 30 (12), 6702-6708.  
14-07-2020
Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer
Angelis V, Tippu Z, Joshi K, Reis S, Gronthoud F, Fribbens C, Okines A, Stanway S et al.
European Journal of Cancer, Elsevier vol. 136, 99-106.  
07-07-2020
Abstract A19: Detection of ESR1 mutations in plasma cell-free DNA from metastatic ER-positive breast cancer patients resistant to hormone therapy
Masotti C, Knebel FH, Linck RDM, Lima J, Shimada AK, Alessi JV, Zucchetti BM, Gerlinger M et al.
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 26 (11_Supplement), a19-a19.  
01-06-2020
Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes
Challoner BR, von Loga K, Woolston A, Griffiths B, Sivamanoharan N, Semiannikova M, Newey A, Barber LJ et al.
Journal of The National Cancer Institute, Oxford University Press (Oup) vol. 113 (1), 88-98.  
23-04-2020
SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer.
Cartwright E, Fong CYK, Hubank M, Saffery C, Kalaitzaki E, Young K, Coyne T, Musallam A et al.
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 38 (4_suppl), tps471-tps471.  
01-02-2020
Author Correction: Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer
von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, Spain G, Challoner B et al.
Nature Communications, Springer Nature vol. 11 (1) 
29-01-2020
Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer
von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, Spain G, Challoner B et al.
Nature Communications, Springer Nature vol. 11 (1) 
16-01-2020
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
Lau D, Kalaitzaki E, Church DN, Pandha H, Tomlinson I, Annels N, Gerlinger M, Sclafani F et al.
Esmo Open, Elsevier vol. 5 (1) 
01-01-2020

2019

Targeted drugs ramp up cancer mutability
Gerlinger M
 
20-12-2019
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment
Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G et al.
Journal For Immunotherapy of Cancer, Bmj vol. 7 (1) 
18-11-2019
661TiP iSCORE: Immunotherapy sequencing in colon and rectal cancer
Turkes FS, Crux R, Cunningham D, Athauda A, Kalaitzaki E, Musallam A, Begum R, De Paepe K et al.
Annals of Oncology, Elsevier vol. 30 
01-10-2019
674PD Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in
Davidson M, Mansukhani S, Starling N, Chau I, Watkins D, Cunningham D, Rao S, Lazaro-Alcausi R et al.
Annals of Oncology, Elsevier vol. 30 
01-10-2019
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M et al.
Cancer Cell, Elsevier vol. 36 (1), 35-50.e9.  
01-07-2019
Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma
Davidson M, Barber LJ, Woolston A, Cafferkey C, Mansukhani S, Griffiths B, Moorcraft S-Y, Rana I et al.
Cancers, Mdpi vol. 11 (5) 
27-05-2019
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Woolston A, Spain G, von Loga K, Challoner B et al.
Journal For Immunotherapy of Cancer, Bmj vol. 7 (1) 
15-04-2019
CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids.
Exposito RG, Semmianikova M, Griffiths B, Khan KH, Barber LJ, Woolston A, Spain G, von Loga K et al.
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 37 (4_suppl), 535-535.  
01-02-2019

2018

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing
Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B et al.
Clinical Chemistry, Oxford University Press (Oup) vol. 64 (11), 1626-1635.  
01-11-2018
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience
Khan K, Rane JK, Cunningham D, Rao S, Watkins D, Starling N, Kalaitzaki E, Forster M et al.
Clinical Colorectal Cancer, Elsevier vol. 18 (1), 64-71.e1.  
29-09-2018
Metastasis Seeding Cells: Lone Invaders or Mass Migrators?
Gerlinger M
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 24 (9), 2032-2034.  
30-04-2018
Complications and seeding risk after percutaneous liver biopsy in an oncological setting.
De Paepe K, Bonne L, Fotiadis N, Starling N, Chau I, Gerlinger M, Rao S, Watkins DJ et al.
 
01-02-2018
Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases.
Bonne L, De Paepe K, Fotiadis N, Starling N, Chau I, Gerlinger M, Rao S, Watkins DJ et al.
 
01-02-2018
Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice
Moorcraft SY, de Castro DG, Cunningham D, Jones T, Walker BA, Peckitt C, Yuan LC, Frampton M et al.
Annals of Oncology, Elsevier vol. 29 (1), 230-236.  
01-01-2018

2017

Circulating tumour DNA, a promising biomarker for the management of colorectal cancer
Khakoo S, Georgiou A, Gerlinger M, Cunningham D, Starling N
Critical Reviews in Oncology/Hematology, Elsevier vol. 122, 72-82.  
16-12-2017
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer
Lawler M, Alsina D, Adams RA, Anderson AS, Brown G, Fearnhead NS, Fenwick SW, Halloran SP et al.
Gut, Bmj vol. 67 (1) 
12-12-2017
Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study
Kayhanian H, Goode E, Sclafani F, Ang JE, Gerlinger M, de Castro DG, Shepherd S, Peckitt C et al.
Clinical Colorectal Cancer, Elsevier vol. 17 (1), e69-e76.  
16-10-2017
Classifying the evolutionary and ecological features of neoplasms
Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M et al.
Nature Reviews Cancer, Springer Nature vol. 17 (10), 605-619.  
15-09-2017
Cancer (r)evolution
von Loga K, Gerlinger M
Nature Ecology & Evolution, Springer Nature vol. 1 (8), 1051-1052.  
21-07-2017
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters
Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong YNS, King H et al.
Annals of Oncology, Elsevier vol. 28 (10), 2472-2480.  
19-07-2017
Abstract 422: Lymph node metastasis evolution drives immune evasion and targeted therapy resistance in gastro-esophageal adenocarcinomas (GEAs)
Davies MN, Barber LJ, Spain G, Lopes F, Loga KV, Griffiths B, Woolston A, Alpar D et al.
 
01-07-2017
PD-015 Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in a predominanty gastrointestinal oncology patient population, treated at the Royal Marsden (RM) Hospital
Khan K, Expósito RG, Cunningham D, Koh D-M, Woolston A, Kouvelakis K, Bali M, Mccall J et al.
Annals of Oncology, Elsevier vol. 28 
01-06-2017
Visualization of intra tumor heterogeneity by simultaneous analysis of tumor and liquid biopsy samples in stage M neuroblastomas
Gerber T, Barber L, Huetter S, Bogen D, Davies M, Assiotis I, Berneder M, Abbasi R et al.
30. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch-onkologische Forschung. 
01-05-2017

2016

Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma
Crusz SM, Tang YZ, Sarker S-J, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A et al.
Bmc Medicine, Springer Nature vol. 14 (1) 
14-11-2016
A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result.
Khan KH, Rata M, Koh D-M, Tunariu N, Collins DJ, Chau I, Watkins DJ, Starling N et al.
 
01-02-2016
Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine
Lipinski KA, Barber LJ, Davies MN, Ashenden M
Trends in Cancer, Elsevier vol. 2 (1), 49-63.  
01-01-2016

2015

Genetic Intratumor Heterogeneity
Alpar D, Barber LJ
In Epigenetic Cancer Therapy 571-593.  
22-07-2015
P-309 PROSPECT-R: A PROSPECTive translational study investigating molecular predictors of resistance and response to Regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (CRC)
Khan K, Chau I, Gerlinger M, Valeri N, Koh D-M, Starling N, Watkins D, Rao S et al.
 
01-06-2015
SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair
Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M et al.
Oncogene, Springer Nature vol. 34 (46), 5699-5708.  
02-03-2015
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome
Favero F, McGranahan N, Salm M, Birkbak NJ, Sanborn JZ, Benz SC, Becq J, Peden JF et al.
Annals of Oncology, Elsevier vol. 26 (5), 880-887.  
02-03-2015
Translating Seminoma Genomic Landscapes into Clinical Practice
Gerlinger M
European Urology, Elsevier vol. 68 (1), 84-85.  
02-02-2015
Intratumor heterogeneity of DNA copy number aberrations in gastric and oesophageal adenocarcinomas.
Davies MN, Alpar D, Griffiths B, Barber LJ, Lipinski KA, Eltahir Z, Wotherspoon A
 
20-01-2015
Chapter 24 Genetic Intratumor Heterogeneity
Alpar D, Barber LJ
In Epigenetic Cancer Therapy, Elsevier 571-593.  
01-01-2015

2014

Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale
Barber LJ, Davies MN
Current Opinion in Genetics & Development, Elsevier vol. 30, 1-6.  
31-12-2014
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S et al.
Science, American Association For The Advancement of Science (Aaas) vol. 346 (6206), 251-256.  
10-10-2014
Cancer: Evolution Within a Lifetime
Gerlinger M, McGranahan N, Dewhurst SM, Burrell RA, Tomlinson I, Swanton C
Annual Review of Genetics, Annual Reviews vol. 48 (1), 1-22.  
01-10-2014
Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers
Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, Pickering L, Gore M et al.
European Urology, Elsevier vol. 66 (5), 936-948.  
19-07-2014
Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications
Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C
European Urology, Elsevier vol. 67 (4), 729-737.  
02-05-2014
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N et al.
Nature Genetics, Springer Nature vol. 46 (3), 225-233.  
02-02-2014
The promise of circulating tumor cell analysis in cancer management
Mateo J, Gerlinger M, Rodrigues DN, de Bono JS
Genome Biology, Springer Nature vol. 15 (8) 
01-01-2014
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution
Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, McGranahan N, Stares M et al.
Genome Biology, Springer Nature vol. 15 (8) 
01-01-2014

2013

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer
Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A et al.
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 19 (24), 6924-6934.  
15-12-2013
Computational optimisation of targeted DNA sequencing for cancer detection
Martinez P, McGranahan N, Birkbak NJ, Gerlinger M, Swanton C
Scientific Reports, Springer Nature vol. 3 (1) 
03-12-2013
Ultra‐deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas
Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N et al.
The Journal of Pathology, Wiley vol. 231 (4), 424-432.  
12-11-2013
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Gerlinger M, Norton L, Swanton C
The New England Journal of Medicine, Massachusetts Medical Society vol. 369 (12), 1172-1173.  
19-09-2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1.
Awad MM, Engelman JA, Shaw AT
The New England Journal of Medicine vol. 369 (12) 
01-09-2013
Parallel evolution of tumour subclones mimics diversity between tumours
Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell RA, Rowan AJ, Joshi T, Fisher R et al.
The Journal of Pathology, Wiley vol. 230 (4), 356-364.  
09-07-2013
Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma
Khattak MA, Bakr F, Krzystanek M, Szallasi Z, Gerlinger M, Santos C, Swanton C, Pickering LM et al.
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 31 (7), 971-972.  
07-01-2013

2012

The authors reply
Swanton C, Larkin J, Gerlinger M
New England Journal of Medicine vol. 366 (22) 
31-05-2012
Genome‐wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target
Gerlinger M, Santos CR, Spencer‐Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M et al.
The Journal of Pathology, Wiley vol. 227 (2), 146-156.  
18-04-2012
Intratumor Heterogeneity: Seeing the Wood for the Trees
Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C
Science Translational Medicine, American Association For The Advancement of Science (Aaas) vol. 4 (127) 
28-03-2012
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P et al.
The New England Journal of Medicine, Massachusetts Medical Society vol. 366 (10), 883-892.  
08-03-2012

2010

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Gerlinger M, Swanton C
 
01-10-2010
Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy
Gerlinger M, Wilson P, Shamash J
European Journal of Cancer, Elsevier vol. 46 (16), 2913-2918.  
13-08-2010
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M et al.
Genome Medicine, Springer Nature vol. 2 (8) 
11-08-2010
Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference
Tan DS-W, Gerlinger M, Teh B-T, Swanton C
European Journal of Cancer, Elsevier vol. 46 (12), 2166-2177.  
21-04-2010
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials
Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E et al.
The Lancet Oncology, Elsevier vol. 11 (4), 358-365.  
26-02-2010
Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management
Gerlinger M, Rohatiner AZS, Matthews J, Davies A
Haematologica, Ferrata Storti Foundation (Haematologica) vol. 95 (7), 1130-1135.  
27-01-2010

2009

951 ESTABLISHED PROGNOSTIC MODELS FAIL TO PREDICT THE OUTCOME OF DOSE DENSE CHEMOTHERAPY FOR THE TREATMENT OF RECURRENT GERM CELL TUMOURS (GCTS)
Gerlinger M, Wilson P, Powles T, Oliver RTD, Shamash J
European Urology Open Science, Elsevier vol. 8 (4) 
01-03-2009

2008

Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma.
Gerlinger M, Matthews J, Lister TA, Montoto S
Blood, American Society of Hematology vol. 112 (11) 
16-11-2008
Non-castrate status at the end of chemotherapy for metastatic hormone-resistant prostate cancer (HRPC) correlates with a better overall survival
Gerlinger M, Wilson P, Powles T, Shamash J
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 26 (15_suppl), 16102-16102.  
20-05-2008

2006

Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients
Walton SM, Gerlinger M, de la Rosa O, Nuber N, Knights A, Gati A, Laumer M, Strauss L et al.
The Journal of Immunology, Oxford University Press (Oup) vol. 177 (11), 8212-8218.  
01-12-2006

2005

Egr-1 Induces the Expression of Its Corepressor Nab2 by Activation of the Nab2 Promoter Thereby Establishing a Negative Feedback Loop*
Kumbrink J, Gerlinger M, Johnson JP
Journal of Biological Chemistry, Elsevier vol. 280 (52), 42785-42793.  
31-10-2005

Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial data
Khan K, exposito RG, Cunningham D, Koh D-M, Woolston A, Barber L, Griffins B, Kouvelakis K et al.
In Medrxiv 
Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error corrected circulating tumour DNA sequencing
Mansukhani S, Barber LJ, Moorcraft SY, Davidson M, Woolston A, Griffiths B, Fenwick K, Herman B et al.
In Biorxiv 
Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer
Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Exposito RG, Patil Y, Mansukhani S et al.
In Biorxiv 
Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer
Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, Anandappa G, Crux R et al.
In Biorxiv 
Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer
von Loga K, Woolston A, Punta M, Barber L, Griffiths B, Semiannikova M, Spain G, Challoner B et al.
In Biorxiv 
Mutational processes impact the evolution of anti-EGFR antibody resistance in colorectal cancer
Woolston A, Barber LJ, Griffiths B, Matthews N, Rao S, Watkins D, Chau I, Starling N et al.
In Biorxiv 
Multifactorial remodeling of the cancer immunopeptidome by interferon gamma
Newey A, Yu L, Barber LJ, Choudhary JS, Bassani-Sternberg M, Gerlinger M
In Biorxiv